Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Save yourself first. Unless it's too late.
If it's too late then go earn some more and short you thoughts.
TIA
HOBO
PS. If I could just put money in one fellows pocket that doesn't have any, I feel that would be great.
I'll take a wager on that...
Nothing like putting your money where your mouth is...
Email me....
TIA
HOBO
>The evaluation of iron that have the two mining companies is 400 thousand to 500 thousand tons and talk of a potential that can be expanded to one million tons. <
1B on deck!
HOBO
I was in there Friday buying and I hope there is another drop on Tuesday. This has come down to almost where first started buying.
I 'd say I will pick up few more million shares.
I know there is risk here, but if you want a big payday you gotta buy before the #'s hit the SEC's and the stock explodes...
Looking forward to the next few months as iron ore spot prices are moving up every week and are expected to top $300 which is almost double.
This means it is possible to have a 50m to 75m Q2.
What I believe....
We are mining iron ore.
There is ore to be shipped.
There is plenty more iron ore in our mines.
Revs will top 30m first Q.
The CE mark is not a material problem.
The PPS will continue to rise.
HOBO
This is a little of what needs to be done....
Alternative Reporting Standard:
Guidelines for Providing Adequate Current Information
Pink OTC Markets encourages all issuers of OTC equity securities to make adequate current information available to the public markets. Pink OTC Markets believes that federal securities laws, such as Rules 10b-5 and 15c2-11 of the Securities Exchange Act of 1934 (“Exchange Act”), and Rule 144 of the Securities Act of 1933 (“Securities Act”), and state Blue Sky laws require issuers to provide adequate current public information. With a view to encouraging compliance with these laws, Pink OTC Markets has created these Guidelines for Providing Adequate Current Information (“Guidelines”) in order to assist issuers with understanding their disclosure obligations under the Alternative Reporting Standard.1
Pink OTC Markets believes adequate current information must be publicly available when an issuer’s securities are quoted by a broker-dealer under the following circumstances:
•
At the time of initial quotation in public markets;
•
At any time corporate insiders or other affiliates of the issuer are offering, buying or selling the issuer’s securities in the OTC market;
•
During any period when a security is the subject of ongoing promotional activities having the effect of encouraging trading of the issuer’s securities in the OTC market;
•
At the time securities initially sold in a private placement become freely tradable in the OTC market; or
•
At any time the issuer’s securities are quoted on OTCQX or included in the Current Information OTC Market Tier.
Issuers with securities listed on OTCQX International are providing adequate current information because such issuers either (i) have a class of their securities registered with the Securities and Exchange Commission (“SEC”) under Section 12(g) of the Exchange Act and are current in their SEC reporting obligations or (ii) are non-U.S. issuers that are exempt from registration pursuant to Exchange Act Rule 12g3-2(b), are current and fully compliant with their obligations thereunder, and have posted the information required to be made publicly available pursuant to Exchange Act Rule 12g3-2(b), in English via the OTC Disclosure and News Service.
These Guidelines may be amended from time to time, in the sole and absolute discretion of Pink OTC Markets, with or without notice.
1 This is not legal advice, and Pink OTC Markets cannot assure anyone that compliance with our disclosure requirements will satisfy any legal requirements.
Version 9.7 Updated on 07/22/2009 Page 2 of 39
Table of Contents
General Considerations........................................................................................................................................................4
Section One: Issuers’ Initial Disclosure Obligations...........................................................................................................5
Part A General Company Information............................................................................................................................5
Item I The exact name of the issuer and its predecessor (if any)...............................................................................5
Item II The address of the issuer’s principal executive offices..................................................................................5
Item III The jurisdiction(s) and date of the issuer’s incorporation or organization.....................................................5
Part B Share Structure.....................................................................................................................................................6
Item IV The exact title and class of securities outstanding.........................................................................................6
Item V Par or stated value and description of the security..........................................................................................6
Item VI The number of shares or total amount of the securities outstanding for each class of securities authorized.6
Part C Business Information...........................................................................................................................................6
Item VII The name and address of the transfer agent*...............................................................................................6
Item VIII The nature of the issuer’s business..............................................................................................................7
Item IX The nature of products or services offered....................................................................................................9
Item X The nature and extent of the issuer’s facilities..............................................................................................10
Part D Management Structure and Financial Information.............................................................................................10
Item XI The name of the chief executive officer, members of the board of directors, as well as control persons....10
Item XII Financial information for the issuer’s most recent fiscal period................................................................14
Item XIII Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence................................................................................................................................15
Item XIV Beneficial Owners...................................................................................................................................15
Item XV The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to the operations, business development and disclosure:....................................15
Item XVI Management’s Discussion and Analysis or Plan of Operation.................................................................16
Part E Issuance History.................................................................................................................................................20
Item XVII List of securities offerings and shares issued for services in the past two years.....................................20
Part F Exhibits..............................................................................................................................................................21
Item XVIII Material Contracts.................................................................................................................................21
Item XIX Articles of Incorporation and Bylaws.......................................................................................................22
Item XX Purchases of Equity Securities by the Issuer and Affiliated Purchasers....................................................22
Item XXI Issuer’s Certifications..............................................................................................................................24
Section Two: Issuers’ Continuing Disclosure Obligations...............................................................................................26
Quarterly Reporting Obligations......................................................................................................................................26
Item I Exact name of the issuer and the address of its principal executive offices..................................................26
Item 2 Shares outstanding........................................................................................................................................27
Item 3 Interim financial statements..........................................................................................................................27
Item 4 Management’s discussion and analysis or plan of operation.........................................................................27
Item 5 Legal proceedings.........................................................................................................................................27
Item 6 Defaults upon senior securities.....................................................................................................................27
Item 7 Other information.........................................................................................................................................28
Item 8 Exhibits.........................................................................................................................................................28
Item 9 Certifications................................................................................................................................................28
Annual Reporting Obligations..........................................................................................................................................28
Current Reporting Obligations.........................................................................................................................................29
1. Entry into a Material Definitive Agreement..........................................................................................................29
2. Termination of a Material Definitive Agreement..................................................................................................30
Version 9.7 Updated on 07/22/2009 Page 3 of 39
3. Completion of Acquisition or Disposition of Assets, Including but not Limited to Mergers...............................30
4. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of an Issuer............................................................................................................................................................................31
5. Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.........................................................................................................................................32
6. Costs Associated with Exit or Disposal Activities................................................................................................33
7. Material Impairments...........................................................................................................................................33
8. Sales of Equity Securities.....................................................................................................................................34
9. Material Modification to Rights of Security Holders............................................................................................34
10. Changes in Issuer's Certifying Accountant.........................................................................................................34
11. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.........................................................................................................................................................................36
12. Changes in Control of Issuer..............................................................................................................................37
13. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers...........37
14. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year....................................................38
15. Amendments to the Issuer's Code of Ethics, or Waiver of a Provision of the Code of Ethics............................38
Version 9.7 Updated on 07/22/2009 Page 4 of 39
General Considerations
An issuer preparing a disclosure statement under the Alternative Reporting Standard shall consider the purpose of adequate disclosure. Current and potential investors in the issuer’s securities should be provided with all “material” information ? the information available to the issuer necessary for the investor to make a sound investment decision. The disclosure should enable an investor of ordinary intelligence and investment skills to understand the issuer’s business and prospects.
The disclosure must therefore present the issuer’s business plan and include a full and clear picture of the issuer’s assets, facilities, properties, investments, management and other resources, as well as a complete description of how they will be used to make profits. The issuer’s business plan should clearly describe the competition, regulatory environment and other risks to the issuer’s business, as well as the issuer’s plans for confronting these challenges.
It is also important for an investor to understand how the issuer raises capital and treats investors. At a minimum, the issuer must describe the ways it has raised capital by issuing shares in the past – to whom and the amount of consideration involved. The investor should also be provided with market information, including the past price history of any transactions in the issuer’s shares.
Finally, the disclosure should use plain English.2 This means using short sentences, avoiding legal and technical jargon and providing clear descriptions. Your goal, as an issuershould be to give the investor the information you would wish the investor to supply if your positions were reversed. You don’t need to be Shakespeare; you must, though, have a sincere desire to
2 For tips, you may wish to consult the SEC’s Plain English Handbook, available for free on the SEC’s website, at http://www.sec.gov.
Version 9.7 Updated on 07/22/2009 Page 5 of 39
Section One: Issuers’ Initial Disclosure Obligations
Instructions relating to the preparation of initial disclosure statements:
Issuers shall prepare a document that responds to each item and sub-item of the Guidelines with information current as of the issuer’s most recent fiscal quarter or year end and shall include in its response to a particular item (i) whether a particular item is not applicable or unavailable and (ii) the reason it is not applicable or unavailable. The disclosure statement shall be provided in the format set forth below.
Issuers may incorporate by reference financial statements and other exhibits that are either posted elsewhere through the OTC Disclosure and News Service or on SEC’s EDGAR system, or are attached to the issuer’s disclosure statement, as long as (i) the incorporated documents are current, (ii) the issuer clearly explains where the incorporated documents can be found, and (iii) the issuer provides a clear cross-reference to the specific location where the information requested by any particular Item can be found in the incorporated documents.
The initial disclosure statement shall be published through the OTC Disclosure and News Service under the report name of “Initial Company Information and Disclosure Statement.”
Part A General Company Information
Item I The exact name of the issuer and its predecessor (if any).
In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.
Item II The address of the issuer’s principal executive offices.
In answering this item, please also provide (i) the telephone and fax number of the issuer’s principal executive offices, (ii) if applicable, the URL of each website maintained by or on behalf of the issuer, and (iii) if applicable, the name, phone number, email address, and mailing address of the person responsible for the issuer’s investor relations.
Item III The jurisdiction(s) and date of the issuer’s incorporation or organization.
Provide the issuer’s jurisdiction(s) of incorporation or jurisdiction(s) of organization (if the issuer is not a corporation) and the date on which it was incorporated or organized.
Version 9.7 Updated on 07/22/2009 Page 6 of 39
Part B Share Structure
Item IV The exact title and class of securities outstanding.
In answering this item, provide the exact title and class of each class of outstanding securities. In addition, please provide the CUSIP and trading symbol.
Item V Par or stated value and description of the security.
A. Par or Stated Value. Provide the par or stated value for each class of outstanding securities.
B. Common or Preferred Stock.
1.
For common equity, describe any dividend, voting and preemption rights.
2.
For preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions.
3.
Describe any other material rights of common or preferred stockholders.
4.
Describe any provision in issuer’s charter or by-laws that would delay, defer or prevent a change in control of the issuer.
Item VI The number of shares or total amount of the securities outstanding for each class of securities authorized.
In answering this item, provide the information below for each class of securities authorized. Please provide this information (i) as of the end of the issuer’s most recent fiscal quarter and (ii) as of the end of the issuer’s last two fiscal years.
(i)
Period end date;
(ii)
Number of shares authorized;
(iii)
Number of shares outstanding;
(iv)
Freely tradable shares (public float);
(v)
Total number of beneficial shareholders; and
(vi)
Total number of shareholders of record.
Part C Business Information
Item VII The name and address of the transfer agent*.
Version 9.7 Updated on 07/22/2009 Page 7 of 39
In answering this item, please also provide the telephone number of the transfer agent, indicate whether or not the transfer agent is registered under the Exchange Act, and state the appropriate regulatory authority of the transfer agent.
*To be included in OTCQX or the Current Information OTC Market Tier, the issuer’s transfer agent must be registered under the Exchange Act.
Item VIII The nature of the issuer’s business.
In describing the issuer’s business, please provide the following information:
A. Business Development. Describe the development of the issuer and material events during the last three years so that a potential investor can clearly understand the history and development of the business. If the issuer has not been in business for three years, provide this information for any predecessor company. This business development description must also include:
1.
the form of organization of the issuer (e.g., corporation, partnership, limited liability company, etc.);
2.
the year that the issuer (or any predecessor) was organized;
3.
the issuer’s fiscal year end date;
4.
whether the issuer (or any predecessor) has been in bankruptcy, receivership or any similar proceeding;
5.
any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets;
6.
any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;
7.
any change of control;
8.
any increase of 10% or more of the same class of outstanding equity securities;
9.
any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization;
10.
any delisting of the issuer’s securities by any securities exchange or deletion from the OTC Bulletin Board; and
11.
any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a
This is all the info there is on this....
OTC Markets has discontinued the display of quotes on www.otcmarkets.com for this security because it has been labeled Caveat Emptor (Buyer Beware) and because adequate current information has not been made available by the issuer of the securities. It has been labeled Caveat Emptor for one of the following reasons:
* Questionable Promotion — The security is being promoted to the public, but adequate current information about the issuer has not been made available to the public.
* Spam — The security is the subject of spam promotion having the effect of encouraging trading of the issuer's securities.
* Investigation of Fraud — There is a known investigation of fraudulent activity involving the company, its securities or insiders.
* Suspension/Halt — A Regulatory Authority has halted or suspended trading for public interest concerns (i.e. not a news or earning halt).
* Disruptive Corporate Actions — The security or issuer is the subject of corporate actions, such as reverse mergers or serial stocks splits and name changes, without adequate current information being publicly available.
* Unsolicited Quotes — The security has only been quoted on an unsolicited basis since it entered the public markets and the issuer has not made adequate current information available to the public.
* Other Public Interest Concern — There is, in OTC Markets' view, a public interest concern.
Consequently, OTC Markets has removed the quotes from this website until adequate current information is made available by the issuer pursuant to OTC Markets Group's Guidelines for Providing Adequate Current Information (PDF) and until OTC Markets believes there is no longer a public interest concern. Investors are encouraged to use care and due diligence in their investment decisions. Please read our Investor Protection page for more information.
We are ahead of the curve...
Big Biotech joins Big Pharma in hunt for biosimilars
Read more: Big Biotech joins Big Pharma in hunt for biosimilars - FierceBiotech http://www.fiercebiotech.com/story/big-biotech-joins-big-pharma-hunt-biosimilars/2011-01-14#ixzz1B2i1KoCa
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech
Several big biotech and pharma companies have been buzzing about their plans to launch biosimilar programs now that the FDA is laying out a regulatory pathway for the therapies. Reuters pinned down several CEOs at the JP Morgan event, and Amgen's Kevin Sharer as well as Biogen Idec's George Scangos talked up plans to fire up some follow-up programs of their own.
"The next decade will be about access and cost as much as it is about innovation," said Scangos, who added that biosimilars are a "perfect" fit for the company. Sharer, meanwhile, said that Amgen is particularly interested in developing biosimilars for the Asian and Latin American markets, two emerging markets that have become increasingly important in the future of biopharma.
Sign up for our FREE newsletter for more news like this sent to your inbox!
Amgen, of course, is one of the biggest companies to face the first onslaught of biosimilar competition. Scangos picked Amgen's Enbrel, a $3.5 billion biologic, as the first mega-blockbuster on the follow-on hit lit. In addition to the reports from JP Morgan, Merck has been avidly building up its own biosimilar operations. The pharma giant struck a deal this week with the CRO Parexel to develop biosimilars.
Read more: Big Biotech joins Big Pharma in hunt for biosimilars - FierceBiotech http://www.fiercebiotech.com/story/big-biotech-joins-big-pharma-hunt-biosimilars/2011-01-14#ixzz1B2hZvxSk
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech
Pretty simple.....
Nobody wants to get in front of a bear raid. They leverage the money and the kids are afraid of losing the few pennies they have so they take profits or bail. The trick is to see how low you can buy.
So your foolish premise that nobody will buy here is just plain dumb.
Why should anybody buy here, now, anyway. You promised us .005 shares.
Put your sell order in now at .005
I'll take 10m
TIA
HOBO
These fellows are dying here at 8 and they promise 5....
What a failure they are.
Where are the 5's you folks promised.
TIA
HOBO
I surely hope so. But, I know you are FOS. Show me.
I wish I could wager you a few bucks on that call.
HOBO
If it was a fraud it would be different. This is a real company with projected revs over 30m first Q only. Price is only going up on iron ore.
Let me show how it's done.
KEEP SELLING IT'S GOING TO 00.0000001. Notice all caps and the doom and gloom.
When you see this let it fall and start buying. They are going cover.
I want some more 6's or 5's...
HOBO
This is a simile bear raid.....
Notice all the lackey posters and fear mongers. Alias's born when they planned this move. Part of a group that often does this. They get burned too sometimes. But it's easy to do.
I gotta buy more now because I feel this is a solid play.
I want more 6's and 5's....
HOBO
That's why I despise trading otc and PK.
Sometime my orders are large and you can't hit the ask because they just front run you....
Then you gotta wait for a fill. If you wanted a couple of million shares, you will sit there almost a lifetime because the computers are set to trade above that bid.
HOBO
ress Release Source: Cotton & Western Mining, Inc. On Thursday December 30, 2010, 8:30 am EST
HOUSTON, TX--(Marketwire - 12/30/10) - Cotton & Western Mining, Inc. (Pinksheets:CWRN - News) -- Robert L. Cotton, President of Cotton & Western Mining, Inc., says, "The Baja Pacific raw crude iron ore mining project will yield $32,000,000.00 in first quarter revenues as the Company moves November and December finished production to 2011 for sales."
Management is preparing "Mina Guadalupe" for the raining season, spreading more sand on the inside roads, and screening two large stockpiles of -50mm natural materials and the 0-3mm crushed materials together with final finished product 3-18mm raw crude iron ore materials for shipping. The Company is bringing the November and December production forward to the first quarter 2011 for the China Seaborne CFR sales; this combined with the new production in 2011 will yield approximately $32,000,000.00 in first quarter revenues. Beginning in the second quarter of 2011, the Company will increase finished iron ore production to over 100,000 metric tons per month. The mobile processing flow-chart will be configured using closed circuit looping that will incorporate the primary crushing jaw to the secondary crushing cone to the primary screening plant that will loop +18mm back to the cone while feeding the 3-18mm to the magnetic separator and feeding the 1-3mm waste materials to a secondary screening plant that will also feed the magnetic separator while discharging -1mm waste out that will be transported to the waste dumper. The new configuration will eliminate dual handling of materials for screening and processing while producing finished products in sizes 1-18mm for bulk shipments in one continuous operating system.
Year to Date Review:
The Company completed the "Mina Guadalupe" iron mineral mine development in four months, that included all state and federal permitting, land-usage and land access together with surface rights agreements with the land-owners. Mine stripping and extraction preparations were completed under SAMERNAT ECO 120 in 90 days and full mineral extraction began on November the 5th, 2010. Over 200,000 metric tons of various iron minerals and waste materials were processed in less than 60 days, while Management accomplished the development to production of 118,000 metric tons of iron ore within that period of time and coming in $3,000,000.00 under the line item start-up budget. The Company would like to recognize all the management staff of Panamerican Minerals Ventures, S.A. de C.V. (Baja Mexico) that worked tirelessly seven days a week coordinating every detailed item that came up while finding the correct solution for many difficulties that arise while starting a new project in a foreign country together with the mining superintendent Andres Garcia and his hard work and coordination with the mining crews -- all have contributed to the success of the project in the most professional manner.
Related News: China Seaborne Trade, Spot Price Iron Ore may be viewed at the following link:
Metal Bulletin Iron Ore Index Link http://www.mbironoreindex.com/
About Cotton & Western Mining, Inc.
Cotton & Western Mining, Inc. (Pinksheets:CWRN - News), a Nevada Corporation that is engaged in metal mineral exploration, development and operations for "Iron Mineral Mining." For more information, please visit the company's website at www.cottonwestern.com.
Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the Safe Harbors created thereby. The Company is a development stage firm that continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Got filled a few in the 6's...
Not much....
HOBO
so I get to buy more on the cheap...
Thanks.
HOBO
PS I prepared to buy 20m at any moment.
I am LMAO too...
Bought more in the 7's
HOBO
When do you buy, now before the CE is removed or after when the stock is 50% to 100% higher.....
Keep the CE mark til next week....
I am adding now...
I catch the 50% to 100% jump..
HOBO
If it's just not giving an 8k with rev guidance, then buy all you can....
Bought 1m .0086 to .0089
HOBO
The are just about 1 in the same....
HOBO
This guy is sharp....He know his stuff.
Cheap too so he know how to save a dollar. Which works out well for us.
HOBO
Current Time: 11:32 AM Pacific Standard Time, Thursday Jan 13
Current (11:30 AM Pacific Standard Time):
Complete Genomics Flash Windows Media
Rigel Pharmaceuticals Flash Windows Media
ConMed Corporation Flash Windows Media
Amedisys Inc. Flash Windows Media
Coming Up (12:00 PM Pacific Standard Time):
AVI BioPharma
Invacare
Spectrum Pharmaceuticals
IPC The Hospitalist Company, Inc.
I'm thinking that too....
Also all the noise going around the room. We are sure to get get some word of mouth plugs.
HOBO
I'm watching too.....
I don't see a sell-off coming but you never know....
HOBO
Normal coarse of business when a CEO leaves.
Glad he is out. Those shares we eaten up quickly.
HOBO
Listen, I have shares I bought at .03 and .04...
I still added today. I really believe this will be a stock to own.
I suggest you load up.
HOBO
No you can't. This is a must hold.
Notice how all the sellers are out.
If you want shares you gotta pay up.
Bought my last shares this morning a .0611
HOBO
We go up from here....
HOBO
That's now at least 200m due to current prices.
HOBO
I am sure I bought some of his shares.
I am glad they are gone...
HOBO
You make the first shipment to them and then you look for better prices elsewhere.
They will fork over more cash as China needs the coal and the few bucks won't make much of a difference to them.
HOBO
To know what the valuation of VPRO should be we would need to know the final capital structure after the the parts are put in place.
Right now, I believe under all known variables, current O/S, deal with SPPI, Intas relationship, we could possibly see 50 cents short term and could go much higher if the proper structure and financing are done correctly. As the deals, partnerships, and clients come in, expect a major increase in PPS.
We are driving with blinders here so you have to consider this a speculative play. Any real, rational, valuation is pure conjecture.
HOBO
Let me tell you why the financing will be easy.
Simply because the stock trades many shares and will become a darling penny play!
Plan seems firm to me. Utilize Indian scientists at 1/3 the cost. Beautiful model.
VIROPRO will be the first to implement a unique business model that utilizes cross-border strengths from its US and Indian operations to engage in this exciting and promising new field. This model enables VIROPRO to achieve substantial revenues in a relatively short period of time, thereby providing an excellent return to its investors.
? Being a listed company, VIROPRO provides the possibility of several potential exit avenues for its investors.
? The total equity investment by Intas Biopharmaceuticals is estimated at around $3.16 million (~Rs. 158 million).
? A Strategic Partner has expressed interest in a similar level of equity investment with the product off-take commitments from the GMP unit based in India. The choice of a co-investing partner and/or a product off-take commitment would be at VIROPRO‘s discretion.
? VIROPRO now needs a major investor to infuse the funds necessary for implementation and build-out of its strategy.
? VIROPRO has identified several US- and EU bio/pharma companies that have expressed interest in collaborating with VIROPRO and with whom serious discussions are currently underway.
* *
Note: The following total investment by Intas Biopharmaceuticals Ltd., in
BPD, Inc. and/or Viropro, Inc., is reflected in the Projected Balance Sheet
above in the line item, ?Equity Share Capital,? as having already been
invested by Intas:
1. Takeover of BPD, Inc.: $ 628,500 (for 200K shares in 2008)
2. Loan pay-off: $ 146,500 (completed in 2008)
3. Operating funds: $ 200,000 (completed in 2008)
4. Capex & Opex for BPD: $ 250,000 (in 1Q 2009)
5. Takeover of Viropro, Inc: $1,680,000 (by 3Q2009)
6. Capex & Opex for VPRO: $ 250,000 (in 1Q 2010)
7. Total investment by Intas: $3,155,000
The Strategy
• Intas (IBPL) acquired BPD in Poway, CA in late 2008.
• BPD will acquire up to about 55% of ViroPro (a small-cap,
OTC:Nasdaq listed company) by Aug/Sep 2009.
• VPRO being a listed company will be the vehicle for raising
necessary capital for the Global CRAM venture.
• BPD will reverse merge into VPRO.
• Intas’ CRAMS business will become part of VPRO.
• Simultaneous with Term Sheet, VPRO will be renamed (e.g.
PBIO).
• VPRO/PBIO will acquire 51% of European Operation;
financials will be consolidated in VPRO/PBIO.
• VPRO/PBIO will build or acquire 100% of a GMP
manufacturing unit in India.
You gotta remember what he said.....Pennytrader
>Watch and learn boys and girlies<
You must have learned something about him by now.
He is completely FOS.
VPRO to a dollar and beyond...
HOBO
We are looking good all over....
Lets see some news!
HOBO
Done....
New High..
HOBO
We got a little push today...
Good!
Could be the MM covering his short.
HOBO